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radiation. We are reporting this case because of this rare histology and the uncommon presentation of the precursor lesion at the
same time. DAP is regarded as an aggressive disease compared with the AAP with a worse overall and prostate speciﬁc survival.
Commonly, when DAP is found, is already at more advanced stage, with large tumor volumes, high incidence of extra-prostatic
extension and lymph nodes metastasis. DAP is arbitrarily assigned an 8 Gleason score (4 + 4), which describes the behavior of
theses tumors. The intraductal component represents the malignant lumen-spanning proliferation within prostatic ducts and
acini, as in our case, these lesions are found almost exclusively in close proximity to invasive cancer. In summary while most
DAP diagnosed is associated with concomitant AAP with adverse pathology features, a highly selected subset could be found as
pure DAP. In these cases is recommended a clinical management and therapy similar to those for AAP of similar Gleason and
stage, considering androgen-deprivation and adjuvant radiation treatment.
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Background. The position of the PTV in prostate cancer radiotherapy is affected by rectal distension. A distended rectum at the
planning CT scan reduces disease control (1, 2). Dietary and laxative protocols signiﬁcantly reduce rectum distension at the CT
planning scan (3). We tried to work with foreign dietary protocols but they had not result in our environment.
Objectives. To study the feasibility of the new protocol and to compare rectal distension and rectal toxicity in patients before and
after the implementation of the protocol.
Methods. We designed a “Mediterranean adaptation” of the Dutch antiﬂatulent diet published by Smitsmans et al. (3). CT plan-
ning scans before the implementation of protocol were compared against scans of patients subject to the new protocol. Rectal
distension was assessed according to De Crevosier et al. (1). Rectal toxicity was assessed according to RTOG scoring criteria.
Results. Eighty-seven no-protocol patients were compared against 92 protocol patients. The rectal expansion were lower among
the protocol patients with an average CSA of 7.39 (±0.54) cm2 vs. 9.29 (±0.92) cm2; ˛=0.05, p=0.0027. On the other hand, grade 3
acute rectal toxicity (rectal bleeding during radiotherapy) was signiﬁcantly lower among the protocol patients (3% vs. 13%).
Conclusions. This protocol is feasible in our population and reduces rectum distension at the CT planning scan. In addition
rectal bleeding during radiotherapy is signiﬁcantly lower in protocol patients. 1—De Crevoisier et al., IJROBP, 62: 965–973, 2005.
2—Heemsbergen et al., IJROBP, 67: 1418–1424, 2007. 3—Smitsmans et al., IJROBP, 71: 1279–1286, 2008.
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Introduction. Abiraterone acetate (AA), a potent oral CYP17A1 inhibitor is approved for treatment ofmetastatic castration-resistant
prostate cancer (MCRPC) with a survival advantage of 4.9 months.
Purpose. To evaluate the experience in our institution of the AA treatment in MCRPC.
Material and methods. PSA, radiological and clinical responses are retrospectively analysed in patients treated with AA in our
institution.
Results. 12MCRPC received AA across 2012. Median age is 67 (range: 58–83). 6 post-docetaxel, 1 post-estramustine and 4 had not
received chemotherapy before starting AA. 3 patients obtained more than 50% of their PSA levels response after the beginning of
AA, 2 after the ﬁrst 3 months and 1 after the 6 months. 1 obtained a 25% PSA levels response after the 6 ﬁrst months. 3 obtained a
PSA level stabilization, 2 in the ﬁrst 3 months, and 1 in the next 6 months. AA was interrupted in 6 patients, 3 because of a clinical
and PSA progression, and 3 because of toxicity associated with AA. 5 patients are still on treatment with AA; 3 of these underwent
a PSA level progression, but none of them experimented a clinical or radiological progression and maintain asymtomatic.
Conclusions. AA is a well tolerated treatment. Any patient suffered grade 3–4 toxicity. The treatment in metastatic prostate cancer
seems to be very heterogeneous. Consensus about treatment in MCRPC patients should be achieved.
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Introduction. Metastatic castration-resistant prostate adenocarcinoma is deﬁned by disease progression and/or PSA rise with
testosterone levels less than 50ng/dl. Abiraterone acetate inhibits androgen synthesis in all synthesis sources: testicles, adrenal
